A PHASE I/II STUDY OF RUXOLITINIB WITH FRONT-LINE NEOADJUVANT AND POST-SURGICAL THERAPY IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER